BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2903985)

  • 1. Embryopathy in infant conceived one year after termination of maternal etretinate: a reappraisal.
    Lancet; 1988 Nov; 2(8622):1254. PubMed ID: 2903985
    [No Abstract]   [Full Text] [Related]  

  • 2. Embryopathy in infant conceived one year after termination of maternal etretinate.
    Lammer EJ
    Lancet; 1988 Nov; 2(8619):1080-1. PubMed ID: 2903308
    [No Abstract]   [Full Text] [Related]  

  • 3. Malformation of fetus conceived 4 months after termination of maternal etretinate treatment.
    Grote W; Harms D; Jänig U; Kietzmann H; Ravens U; Schwarze I
    Lancet; 1985 Jun; 1(8440):1276. PubMed ID: 2860474
    [No Abstract]   [Full Text] [Related]  

  • 4. [Embryonal malformation following etretinate therapy of Darier's disease in the mother].
    Kietzmann H; Schwarze I; Grote W; Ravens U; Jänig U; Harms D
    Dtsch Med Wochenschr; 1986 Jan; 111(2):60-2. PubMed ID: 3940838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etretinate and pregnancy.
    Lammer E
    Lancet; 1989 Jan; 1(8629):109. PubMed ID: 2562875
    [No Abstract]   [Full Text] [Related]  

  • 6. Etretinate embryotoxicity 7 months after discontinuation of treatment.
    Verloes A; Dodinval P; Koulischer L; Lambotte R; Bonnivert J
    Am J Med Genet; 1990 Nov; 37(3):437-8. PubMed ID: 2260582
    [No Abstract]   [Full Text] [Related]  

  • 7. Teratogenicity of isotretinoin and etretinate.
    Hopf G; Mathias B
    Lancet; 1988 Nov; 2(8620):1143. PubMed ID: 2903358
    [No Abstract]   [Full Text] [Related]  

  • 8. [Teratogenic effects of etretinate in humans].
    Happle R; Traupe H; Bounameaux Y; Fisch T
    Dtsch Med Wochenschr; 1984 Sep; 109(39):1476-80. PubMed ID: 6479047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alcoholic embryopathy].
    Korányi G
    Orv Hetil; 1977 Feb; 118(9):504-7. PubMed ID: 840484
    [No Abstract]   [Full Text] [Related]  

  • 10. [Warfarin embryopathy].
    Galil A; Biale Y; Bar-Ziv J
    Harefuah; 1984 Dec; 107(12):390-2. PubMed ID: 6532923
    [No Abstract]   [Full Text] [Related]  

  • 11. [Embryopathy induced by oral anticoagulants].
    Jullian M; Youlton R; Rivera L
    Rev Med Chil; 1983 Oct; 111(10):1045-8. PubMed ID: 6676812
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug-induced embryopathy--case of multiple developmental anomalies in a newborn infant].
    Maszkiewicz W; Zaniewska J
    Pediatr Pol; 1974 May; 49(5):615-8. PubMed ID: 4830578
    [No Abstract]   [Full Text] [Related]  

  • 13. Teratogenic risk with etretinate and acitretin treatment.
    Geiger JM; Baudin M; Saurat JH
    Dermatology; 1994; 189(2):109-16. PubMed ID: 8075435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retinoids and congenital malformations].
    van der Schroeff JG
    Ned Tijdschr Geneeskd; 1986 Apr; 130(14):622-3. PubMed ID: 3458029
    [No Abstract]   [Full Text] [Related]  

  • 15. [Alcoholic embryopathy (author's transl)].
    Holtorff J; Hinkel GK
    Zentralbl Gynakol; 1981; 103(14):785-96. PubMed ID: 7293549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Picture of the month. Aminopterin embryopathy syndrome.
    Gellis SS; Feingold M
    Am J Dis Child; 1979 Nov; 133(11):1189-90. PubMed ID: 507011
    [No Abstract]   [Full Text] [Related]  

  • 17. [A newborn with extensive abnormalities].
    Kujawa B; Orliński R
    Pol Tyg Lek; 1973 May; 28(16):575-6. PubMed ID: 4705815
    [No Abstract]   [Full Text] [Related]  

  • 18. In-utero exposure to benzodiazepines.
    Lancet; 1987 Mar; 1(8533):627-8. PubMed ID: 2881161
    [No Abstract]   [Full Text] [Related]  

  • 19. [Abnormalities caused by alcohol].
    Neuhäuser G
    Hippokrates; 1974 Nov; 45(4):496-7. PubMed ID: 4465353
    [No Abstract]   [Full Text] [Related]  

  • 20. [Alcoholic embryopathy].
    Holtorff J; Hinkel GK
    Z Gesamte Inn Med; 1981 Aug; 36(16):587-93. PubMed ID: 7027654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.